Nitric oxide-mediated inhibition of Hdm2-p53 binding
dc.contributor.author | Schonhoff, Christopher M. | |
dc.contributor.author | Daou, Marie-Claire | |
dc.contributor.author | Jones, Stephen N. | |
dc.contributor.author | Schiffer, Celia A. | |
dc.contributor.author | Ross, Alonzo H. | |
dc.date | 2022-08-11T08:08:48.000 | |
dc.date.accessioned | 2022-08-23T16:08:43Z | |
dc.date.available | 2022-08-23T16:08:43Z | |
dc.date.issued | 2002-11-13 | |
dc.date.submitted | 2008-12-10 | |
dc.identifier.citation | <p>Biochemistry. 2002 Nov 19;41(46):13570-4.</p> | |
dc.identifier.issn | 0006-2960 (Print) | |
dc.identifier.doi | 10.1021/bi026262q | |
dc.identifier.pmid | 12427017 | |
dc.identifier.uri | http://hdl.handle.net/20.500.14038/32515 | |
dc.description.abstract | It has become increasingly evident that nitric oxide exerts its effects, in part, by S-nitrosylation of cysteine residues. We tested in vitro whether nitric oxide may indirectly control p53 by S-nitrosylation and inactivation of the p53 negative regulator, Hdm2. Treatment of Hdm2 with a nitric oxide donor inhibits Hdm2-p53 binding, a critical step in Hdm2 regulation of p53. The presence of excess amounts of cysteine or dithiothreitol blocks this inhibition of binding. Moreover, nitric oxide inhibition of Hdm2-p53 binding was found to be reversible. Sulfhydryl sensitivity and reversibility are consistent with nitrosylation. Finally, we have identified a critical cysteine residue that nitric oxide modifies to disrupt Hdm2-p53 binding. This cysteine is proximal to the Hdm2-p53 binding interface and is conserved across species from zebrafish to humans. Mutation of this residue from a cysteine to an alanine does not interfere with binding but rather eliminates the sensitivity of Hdm2 to nitric oxide inactivation. | |
dc.language.iso | en_US | |
dc.relation | <p><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=12427017&dopt=Abstract">Link to Article in PubMed</a></p> | |
dc.relation.url | https://doi.org/10.1021/bi026262q | |
dc.subject | Amino Acid Sequence; Binding Sites; Cysteine; Dithiothreitol; Enzyme-Linked Immunosorbent Assay; Glutathione; Glutathione Transferase; Humans; Molecular Sequence Data; Mutagenesis, Site-Directed; Mutation; Neoplasm Proteins; *Nuclear Proteins; Protein Binding; Protein Conformation; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-mdm2; Recombinant Fusion Proteins; Sequence Homology, Amino Acid; Triazenes; Tumor Suppressor Protein p53 | |
dc.subject | Life Sciences | |
dc.subject | Medicine and Health Sciences | |
dc.title | Nitric oxide-mediated inhibition of Hdm2-p53 binding | |
dc.type | Journal Article | |
dc.source.journaltitle | Biochemistry | |
dc.source.volume | 41 | |
dc.source.issue | 46 | |
dc.identifier.legacycoverpage | https://escholarship.umassmed.edu/gsbs_sp/1081 | |
dc.identifier.contextkey | 679619 | |
html.description.abstract | <p>It has become increasingly evident that nitric oxide exerts its effects, in part, by S-nitrosylation of cysteine residues. We tested in vitro whether nitric oxide may indirectly control p53 by S-nitrosylation and inactivation of the p53 negative regulator, Hdm2. Treatment of Hdm2 with a nitric oxide donor inhibits Hdm2-p53 binding, a critical step in Hdm2 regulation of p53. The presence of excess amounts of cysteine or dithiothreitol blocks this inhibition of binding. Moreover, nitric oxide inhibition of Hdm2-p53 binding was found to be reversible. Sulfhydryl sensitivity and reversibility are consistent with nitrosylation. Finally, we have identified a critical cysteine residue that nitric oxide modifies to disrupt Hdm2-p53 binding. This cysteine is proximal to the Hdm2-p53 binding interface and is conserved across species from zebrafish to humans. Mutation of this residue from a cysteine to an alanine does not interfere with binding but rather eliminates the sensitivity of Hdm2 to nitric oxide inactivation.</p> | |
dc.identifier.submissionpath | gsbs_sp/1081 | |
dc.contributor.department | Department of Cell Biology | |
dc.contributor.department | Department of Biochemistry and Molecular Pharmacology | |
dc.contributor.department | Graduate School of Biomedical Sciences | |
dc.source.pages | 13570-4 |